A new multivariate genome-wide association study reveals that obstructive sleep apnea shares a measurable common genetic liability with type 2 diabetes, hypertension, and adiposity. Published in Diabetology & Metabolic Syndrome, the research characterizes the common polygenic component linking these conditions, addressing a long-standing question about why these disorders frequently co-occur. The study, led by Chung-Chih Liao, Ke-Ru Liao, and Jung-Miao Li, integrates European-ancestry genome-wide association studies to derive a latent multivariate factor representing the shared genetic architecture of obstructive sleep apnea and cardiometabolic disease.
The research team utilized Genomic Structural Equation Modeling to integrate data from genome-wide association studies of obstructive sleep apnea, body mass index, type 2 diabetes, and hypertension. This statistical framework enabled the derivation of a latent multivariate obstructive sleep apnea–cardiometabolic disease factor, referred to as mvOSACMD. By modeling these traits simultaneously, the researchers aimed to identify genetic variants that influence the shared variance among these conditions. The methodological design included multivariate genome-wide association studies, locus discovery, and transcriptome-wide association studies with fine-mapping and colocalization. Additionally, the team performed enrichment analyses, single-cell spatial analyses, heritability partitioning, and Polygenic Risk Score estimation using Continuous Shrinkage posterior effect-size methods.
The common-factor model demonstrated a strong fit to the data, with a comparative fit index of 0.968 and a standardized root mean square residual of 0.043. The multivariate genome-wide association study tested 4,844,928 single nucleotide polymorphisms, identifying 553 genomic loci and 808 independent lead variants. SNP-level heterogeneity testing using the QSNP statistic indicated that 799 of these lead variants, representing 98.9 percent, showed no genome-wide significant heterogeneity. Heterogeneous variants were confined to 27 loci, accounting for 4.9 percent of the identified regions. Notably, ninety-five variants reached genome-wide significance in the mvOSACMD factor but did not reach significance in any of the individual input genome-wide association studies, highlighting the power of the multivariate approach to detect shared signals.
Further analysis focused on prioritizing specific genetic variants and genes. Fine-mapping prioritized 33 variants with a mean posterior inclusion probability of at least 0.95 across Sum of Single Effects and FINEMAP methods, including six lead variants. Transcriptome-wide association studies with gene-level fine-mapping prioritized 234 genes. Of these, 101 genes colocalized with the mvOSACMD signal at a posterior probability greater than 0.8.
Enrichment analyses revealed that the prioritized genes and variants are associated with neuronal and neurodevelopmental regulatory programs. Single-cell spatial mapping indicated that the strongest enrichment for these signals occurred in the central nervous system. Specifically, the enrichment peaked in the brain, with a P-value of 1.87 × 10⁻¹⁹, and in the spinal cord, with a P-value of 8.51 × 10⁻¹⁷. Partitioned heritability analysis showed that the genetic signals were enriched in evolutionarily conserved elements and active regulatory annotations.
The study concludes that obstructive sleep apnea and cardiometabolic traits share a measurable common genetic component. The prioritized genes and enriched annotations point specifically to neuronal and neurodevelopmental regulatory programs as key biological pathways. However, the authors note that the specificity of the central nervous system enrichment to the shared factor remains uncertain because the enrichment profiles of the input traits were not directly compared. This limitation highlights the need for further investigation to determine whether the central nervous system signals are unique to the shared factor or also present in the individual traits. The study provides a variant- and gene-level resource that offers hypotheses for functional follow-up research.
While the study identifies a shared genetic architecture, it does not establish a causal relationship between the genetic variants and the clinical outcomes. The findings are based on genetic associations and do not directly translate into clinical predictions or recommendations for individual patients. The authors emphasize that clinical polygenic prediction requires independent validation with individual-level data before it can be applied in a clinical setting.
Subject of Research: Genetic architecture linking obstructive sleep apnea with type 2 diabetes, hypertension, and adiposity
Article Title: Obstructive sleep apnea shares a common genetic liability with type 2 diabetes, hypertension, and adiposity: a multivariate genome-wide association study
Article References: Liao, C.-C., Liao, K.-R., & Li, J.-M. (2026). Obstructive sleep apnea shares a common genetic liability with type 2 diabetes, hypertension, and adiposity: a multivariate genome-wide association study. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-026-02306-w
Image Credits: AI Generated
DOI: 10.1186/s13098-026-02306-w
Keywords: obstructive sleep apnea, type 2 diabetes, hypertension, genomics, cardiometabolic disease, GWAS, genetic liability, neurodevelopment, Obstructive, sleep, apnea, shares
News Source: Juliet Wilcox. (November 8, 2026). Study Links Sleep Apnea Genes to Metabolic Traits. Scienmag.



